Extracapsular Extension of Pelvic Lymph Node Metastasis is an Independent Prognostic Factor in Bladder Cancer: A Systematic Review and Meta-analysis

Annals of Surgical Oncology

Volumn 22, Issue 11, 2015, Pages 3745-3750

  Ahn, Tae Sik ^a   Kim, Hyung Suk ^a   Jeong, Chang Wook ^a   Kwak, Cheol ^a   Kim, Hyeon Hoe ^a   Ku, Ja Hyeon ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CYSTECTOMY; EXTRACAPSULAR EXTENSION; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHATIC PARAMETERS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS LYMPH NODE; PELVIS LYMPH NODE MTASTASIS; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; BLADDER TUMOR; DISEASE FREE SURVIVAL; LYMPH NODE; PATHOLOGY; PELVIS; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; PELVIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84941422114     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4359-1     Document Type: Article

References (31)

1. Kassouf W, Leibovici D, Luongo T, et al. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 2006;107:1491–5.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.
3. Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol. 2005;23:2358–65.
4. Karl A, Carroll PR, Gschwend JE, Knüchel R, Montorsi F, Stief CG, Studer UE. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol. 2009;55:826–35.
5. Stephenson AJ, Gong MC, Campbell SC, Fergany AF, Hansel DE. Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive bladder cancer. Urology. 2010;75:382–6.
6. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003;170:35–41.
7. Wiesner C, Salzer A, Thomas C, Gellermann-Schultes C, Gillitzer R, Hampel C, Thüroff JW. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU Int. 2009;104:331–5.
8. Kassouf W, Agarwal PK, Herr HW, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008;26:121–6.
9. Cascinelli N, Greco M, Bufalino R, et al. Prognosis of breast cancer with axillary node metastases after surgical treatment only. Eur J Cancer Clin Oncol. 1987;23:795–9.
10. Komuta K, Okudaira S, Haraguchi M, Furui J, Kanematsu T. Identification of extracapsular invasion of the metastatic lymph nodes as a useful prognostic sign in patients with resectable colorectal cancer. Dis Colon Rectum. 2001;44:1838–44.
11. Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006;176:1978–82.
12. Srinivas V, Morse MJ, Herr HW, Sogani PC, Whitmore WF Jr. Penile cancer: relation of extent of nodal metastasis to survival. J Urol. 1987;137:880–2.
13. Beck SD, Cheng L, Bihrle R, Donohue JP, Foster RS. Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy? J Urol. 2007;177:944–6.
14. Fleischmann A, Schobinger S, Markwalder R, Schumacher M, Burkhard F, Thalmann GN, Studer UE. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology. 2008;53:468–75.
15. Jeong IG, Ro JY, Kim SC, et al. Extranodal extension in node-positive bladder cancer: the continuing controversy. BJU Int. 2011;108:38–43.
16. Seiler R, von Gunten M, Thalmann GN, Fleischmann A. Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. Histopathology. 2011;58:571–8.
17. Jensen JB, Ulhøi BP, Jensen KM. Evaluation of different lymph node (LN) variables as prognostic markers in patients undergoing radical cystectomy and extended LN dissection to the level of the inferior mesenteric artery. BJU Int. 2012;109:388–93.
18. Nakagawa T, Kanai Y, Nakanishi H, Komiyama M, Fujimoto H. Characteristics of lymph node metastases defining the outcome after radical cystectomy of urothelial bladder carcinoma. Jpn J Clin Oncol. 2012;42:1066–72.
19. Masson-Lecomte A, Vordos D, Hoznek A, et al. External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy. Ann Surg Oncol. 2013;20:1389–94.
20. Fajkovic H, Cha EK, Jeldres C, et al. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. EurUrol. 2013;64:837–45.
21. Fritsche HM, May M, Denzinger S, et al. Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol. 2013;63:739–44.
22. Clifton MM, Psutka SP, Boorjian SA, et al. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World J Urol. 2014. doi:10.1007/s00345-014-1319-0.
23. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
24. De Graeff P, Crijns AP, de Jong S, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 2009;101:149–59.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
27. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
31. Sobin LH, Wittekund C. TNM classification of malignant tumors. 6th edn. New York: Wiley, 2002.